Key result
Higher plasma GDF-15 concentrations were associated with an increased risk of incident chronic kidney disease (OR 1.9 per 1-U increase in log-GDF-15; 95% CI 1.6-2.3; P<0.0001).
Why the study?
Are circulating concentrations of GDF-15, sST2, and hsTnI associated with the development of incident chronic kidney disease in a community cohort?
Cohort (n=2,614)
Are circulating concentrations of GDF-15, sST2, and hsTnI associated with the development of incident chronic kidney disease in a community cohort?
Odds Ratio: 1.9 (95% CI 1.6–2.3)
p-value: p=<0.0001
Higher circulating GDF-15 is independently associated with incident chronic kidney disease and rapid decline in renal function, improving risk prediction beyond standard clinical covariates.
May enhance CKD risk stratification beyond clinical covariates; leaves open causality and need for prospective validation.
BACKGROUND: Growth differentiation factor-15 (GDF-15), soluble ST2 (sST2), and high-sensitivity troponin I (hsTnI) are emerging predictors of adverse clinical outcomes. We examined whether circulating concentrations are related to the development of kidney disease in the community. METHODS: Plasma GDF-15, sST2, and hsTnI concentrations were measured in 2614 Framingham Offspring cohort participants (mean age 57 years, 54% women) at the sixth examination cycle (1995-1998). Associations of biomarkers with incident chronic kidney disease [CKD, eGFR <60 mL · min(-1) · (1.73 m(2)) (-1), n = 276], microalbuminuria (urinary albumin to creatinine ratio ≥25 mg/g in women and 17 mg/g in men, n = 191), and rapid decline in renal function [decline in eGFR ≥3 mL · min(-1) · (1.73 m(2)) (-1) per year, n = 237], were evaluated using multivariable logistic regression; P < 0.006 was considered statistically significant in primary analyses. RESULTS: Participants were followed over a mean of 9.5 years. Higher plasma GDF-15 was associated with incident CKD [multivariable-adjusted odds ratio (OR) 1.9 per 1-U increase in log-GDF-15, 95% CI 1.6-2.3, P < 0.0001] and rapid decline in renal function (OR, 1.6; 95% CI, 1.3-1.8; P < 0.0001). GDF-15, sST2, and hsTnI had suggestive associations with incident microalbuminuria but did not meet the prespecified P-value threshold after multivariable adjustment. Adding plasma GDF-15 to clinical covariates improved risk prediction of incident CKD: the c-statistic increased from 0.826 to 0.845 (P = 0.0007), and categorical net reclassification was 6.3% (95% CI, 2.7-9.9%). CONCLUSIONS: Higher circulating GDF-15 is associated with incident renal outcomes and improves risk prediction of incident CKD. These findings may provide insights into the mechanisms of renal injury.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2013) conducted a cohort in incident chronic kidney disease (n=2,614). Plasma GDF-15 was evaluated on incident chronic kidney disease (OR 1.9, 95% CI 1.6-2.3, p=<0.0001). Higher plasma GDF-15 concentrations were associated with an increased risk of incident chronic kidney disease (OR 1.9 per 1-U increase in log-GDF-15; 95% CI 1.6-2.3; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: